We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ANIP Stock Outlook: Cortrophin Growth vs. Retina Reset
Read MoreHide Full Article
Key Takeaways
ANI Pharmaceuticals' 2025 revenue jumped 43.8% to $883.4M, led by Rare Disease and Brands growth.
ANIP's Cortrophin Gel surged ~76% to $347.8M, becoming its primary specialty growth driver.
ANI Pharmaceuticals expects retina recovery in 2026 after a 2025 reset amid reimbursement challenges.
ANI Pharmaceuticals (ANIP - Free Report) is reshaping its growth profile as specialty therapies take a larger share of the mix. Fiscal 2025 results show accelerating momentum in Rare Disease and Brands, led by Purified Cortrophin Gel, while the legacy Generics business continues to supply steadier cash flow.
The ophthalmology franchise went through a 2025 transition year. Management is positioning the retina portfolio for a return to growth in 2026, even as near-term seasonality creates an uneven start to the year.
ANIP’s Growth Mix Is Shifting Toward Rare Disease
ANI’s top-line momentum is increasingly driven by its Rare Disease franchise. Cortrophin Gel has become the centerpiece of the company’s specialty strategy, shifting the growth engine toward proprietary branded therapeutics.
Generics and Other is no longer the primary growth driver, but it remains a stable cash-flow base. That steadier contribution can help support investment in specialty commercialization and ongoing product launches.
ANI Pharmaceuticals’ 2025 Revenue Base and Segment Split
Fiscal 2025 total revenue was $883.4 million, up 43.8% year over year. ANI reports two operating segments: Rare Disease and Brands, and Generics and Other.
Rare Disease and Brands contributed $484.0 million, or 54.8% of total revenue. Generics and Other contributed $399.4 million, or 45.2%.
Revenue is primarily U.S.-derived, with $852.4 million generated in the United States and $30.9 million internationally from direct operations and partnerships.
Cortrophin Gel delivered $347.8 million of revenue in 2025 and grew about 76% year over year. That scale and growth rate makes it the company’s clear specialty anchor.
The durability case rests on under-penetration in addressable markets and expanding adoption across multiple specialties. ANI is reinforcing that demand backdrop with targeted commercial execution to broaden prescribing depth.
The prefilled syringe formulation has improved ease of use and gained rapid traction, accounting for a majority of new patient starts. ANI is also building a dedicated ~90-person sales force aimed at acute gouty arthritis flares to widen access into a large, under-tapped patient population.
ANI Pharmaceuticals’ Ophthalmology Franchise Had 2025 Headwinds
The retina franchise generated $74.9 million in combined Iluvien/Yutiq revenue in 2025, but performance was pressured by reimbursement and inventory dynamics at physician offices. Market access challenges also weighed on demand.
Funding constraints affecting patient assistance programs for Medicare beneficiaries added friction. Management characterized 2025 as a “reset year,” consolidating Iluvien and Yutiq into a unified Iluvien brand to streamline promotion across both diabetic macular edema and chronic non-infectious uveitis affecting the posterior segment indications.
Management expects the franchise to return to growth in 2026, supported by the post-consolidation commercial approach and guidance that implies year-over-year improvement.
ANIP’s 2026 Setup Blends Guidance and Seasonality
Management reaffirmed fiscal 2026 guidance for total net revenue of $1.06-$1.10 billion and Cortrophin revenue of $540-$575 million. The outlook also includes adjusted non-GAAP EBITDA of $275-$290 million, adjusted non-GAAP earnings per share of $8.83-$9.34, and adjusted gross margin of 59.3%-60.3%.
Cortrophin is expected to start the year with a timing-related headwind. First-quarter 2026 Cortrophin revenue is expected to be about 13%-14% of full-year sales, below the roughly 15% contribution seen in the year-ago period, due to insurance reverifications and winter disruptions.
Sequential acceleration is expected as the year progresses and the mid-2026 gout team is deployed, creating a setup where quarterly cadence may matter as much as full-year totals.
ANI Pharmaceuticals’ Key Risks: Competition and Concentration
Competitive intensity is a central risk across ANI’s specialty portfolio. Cortrophin Gel’s primary competitor is Acthar Gel, marketed by Keenova Therapeutics, and both products are seeing momentum in targeted markets.
In ophthalmology, Iluvien competes against AbbVie (ABBV - Free Report) through Ozurdex and against anti-vascular endothelial growth factor options that include Regeneron Pharmaceuticals (REGN - Free Report) via the Eylea and Eylea HD franchise.
Customer concentration adds another layer of risk. In 2025, three wholesale customers accounted for 53% of total net revenue and represented 64% of accounts receivable, which can amplify pricing and working-capital volatility if buyer leverage increases.
View the Zacks #1 Rank List
Image: Bigstock
ANIP Stock Outlook: Cortrophin Growth vs. Retina Reset
Key Takeaways
ANI Pharmaceuticals (ANIP - Free Report) is reshaping its growth profile as specialty therapies take a larger share of the mix. Fiscal 2025 results show accelerating momentum in Rare Disease and Brands, led by Purified Cortrophin Gel, while the legacy Generics business continues to supply steadier cash flow.
The ophthalmology franchise went through a 2025 transition year. Management is positioning the retina portfolio for a return to growth in 2026, even as near-term seasonality creates an uneven start to the year.
ANIP’s Growth Mix Is Shifting Toward Rare Disease
ANI’s top-line momentum is increasingly driven by its Rare Disease franchise. Cortrophin Gel has become the centerpiece of the company’s specialty strategy, shifting the growth engine toward proprietary branded therapeutics.
Generics and Other is no longer the primary growth driver, but it remains a stable cash-flow base. That steadier contribution can help support investment in specialty commercialization and ongoing product launches.
ANI Pharmaceuticals’ 2025 Revenue Base and Segment Split
Fiscal 2025 total revenue was $883.4 million, up 43.8% year over year. ANI reports two operating segments: Rare Disease and Brands, and Generics and Other.
Rare Disease and Brands contributed $484.0 million, or 54.8% of total revenue. Generics and Other contributed $399.4 million, or 45.2%.
Revenue is primarily U.S.-derived, with $852.4 million generated in the United States and $30.9 million internationally from direct operations and partnerships.
ANI Pharmaceuticals, Inc. Price and Consensus
ANI Pharmaceuticals, Inc. price-consensus-chart | ANI Pharmaceuticals, Inc. Quote
ANIP’s Cortrophin Gel Is the Main Revenue Driver
Cortrophin Gel delivered $347.8 million of revenue in 2025 and grew about 76% year over year. That scale and growth rate makes it the company’s clear specialty anchor.
The durability case rests on under-penetration in addressable markets and expanding adoption across multiple specialties. ANI is reinforcing that demand backdrop with targeted commercial execution to broaden prescribing depth.
The prefilled syringe formulation has improved ease of use and gained rapid traction, accounting for a majority of new patient starts. ANI is also building a dedicated ~90-person sales force aimed at acute gouty arthritis flares to widen access into a large, under-tapped patient population.
ANI Pharmaceuticals’ Ophthalmology Franchise Had 2025 Headwinds
The retina franchise generated $74.9 million in combined Iluvien/Yutiq revenue in 2025, but performance was pressured by reimbursement and inventory dynamics at physician offices. Market access challenges also weighed on demand.
Funding constraints affecting patient assistance programs for Medicare beneficiaries added friction. Management characterized 2025 as a “reset year,” consolidating Iluvien and Yutiq into a unified Iluvien brand to streamline promotion across both diabetic macular edema and chronic non-infectious uveitis affecting the posterior segment indications.
Management expects the franchise to return to growth in 2026, supported by the post-consolidation commercial approach and guidance that implies year-over-year improvement.
ANIP’s 2026 Setup Blends Guidance and Seasonality
Management reaffirmed fiscal 2026 guidance for total net revenue of $1.06-$1.10 billion and Cortrophin revenue of $540-$575 million. The outlook also includes adjusted non-GAAP EBITDA of $275-$290 million, adjusted non-GAAP earnings per share of $8.83-$9.34, and adjusted gross margin of 59.3%-60.3%.
Cortrophin is expected to start the year with a timing-related headwind. First-quarter 2026 Cortrophin revenue is expected to be about 13%-14% of full-year sales, below the roughly 15% contribution seen in the year-ago period, due to insurance reverifications and winter disruptions.
Sequential acceleration is expected as the year progresses and the mid-2026 gout team is deployed, creating a setup where quarterly cadence may matter as much as full-year totals.
ANI Pharmaceuticals’ Key Risks: Competition and Concentration
Competitive intensity is a central risk across ANI’s specialty portfolio. Cortrophin Gel’s primary competitor is Acthar Gel, marketed by Keenova Therapeutics, and both products are seeing momentum in targeted markets.
In ophthalmology, Iluvien competes against AbbVie (ABBV - Free Report) through Ozurdex and against anti-vascular endothelial growth factor options that include Regeneron Pharmaceuticals (REGN - Free Report) via the Eylea and Eylea HD franchise.
Customer concentration adds another layer of risk. In 2025, three wholesale customers accounted for 53% of total net revenue and represented 64% of accounts receivable, which can amplify pricing and working-capital volatility if buyer leverage increases.
ANIP’s Zacks Rank
ANI Pharmaceuticals currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.